ライフサイエンスコーパス: marrow biopsy

1 ith tryptase in estimating the need for bone marrow biopsy.

2 mastocytosis) and thus candidates for a bone marrow biopsy.

3 aggregates, and atypical mast cells on bone marrow biopsy.

4 94% and 100% for PET-CT and 40% and 100% for marrow biopsy.

5 ent accuracy to replace routine staging bone marrow biopsy.

6 e to up to 31 drugs within 5 days after bone marrow biopsy.

7 e of biopsy site than the usual random iliac marrow biopsy.

8 ne and serum immunoelectrophoresis, and bone marrow biopsy.

9 diagnosis usually depends on results of bone marrow biopsy.

10 the potential to reduce the need for staging marrow biopsy.

11 re red cell aplasia (PRCA) confirmed by bone marrow biopsy.

12 with hematologic response criteria and bone marrow biopsies.

13 ot density compared with normal control bone marrow biopsies.

14 relevance of expression in 55 archival bone marrow biopsies.

15 loid leukemia (AML) routinely undergo a bone marrow biopsy 7-10 days after induction chemotherapy to

16 Analysis of bone marrow biopsies after CTL019 revealed 8 patients with pe

17 Response was assessed by weekly CBC and bone marrow biopsy after cycle 2 and after each subsequent cy

18 Bone marrow biopsy analysis showed 5% plasma cells, which sta

19 tochemically by factor VIII staining of bone marrow biopsies and quantified by assessment of microves

20 s of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothelial g

21 Five patients were upstaged by marrow biopsy and 7 by contrast-enhanced CT in the bowel

22 The patient's bone marrow biopsy and aspirate displayed unique pathologic f

23 and negligible gene marking, diagnostic bone marrow biopsy and aspirate were performed at day 88.

24 A bone marrow biopsy and aspiration revealed a mildly hypercell

25 myeloma was diagnosed and confirmed by bone marrow biopsy and aspiration.

26 Congo red stain on bone marrow biopsy and fat pad aspirate was negative for amyl

27 ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac

28 ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac

29 up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical and histochemical

30 is, in the selection of those needing a bone marrow biopsy, and in the documentation of disease progr

31 2005 had data extracted from staging PET-CT, marrow biopsy, and treatment records.

32 o identify those patients who require a bone marrow biopsy, and whether the pathogenesis of IA involv

33 suspicious lymphocytic infiltrates in a bone marrow biopsy as the sole suggestion of residual disease

34 adioimmunotherapy, after lymph node and bone marrow biopsies at 2-4 and/or 19 h after injection.

35 he diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according to m

36 etastatic CRPC who underwent transiliac bone marrow biopsy between October 2007 and March 2010.

37 ll lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marrow inv

38 Skin and bone marrow biopsies can thus be used to generate de novo fun

39 A percutaneous biopsy of the mass and bone marrow biopsy confirmed the diagnosis of primary adrenal

40 rum paraproteins and/or light chains or bone marrow biopsy defined response.

41 inal mass was discovered, and tumor and bone marrow biopsies disclosed rhabdomyosarcoma.

42 ide therapy should undergo surveillance bone marrow biopsy every 2 to 3 years and that those who show

43 Bone marrow biopsy exhibited mostly mixed patterns of small B

44 icaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggregates

45 ed at the protein level by immunostaining of marrow biopsies for NY-ESO-1.

46 esis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients.

47 We evaluated bone marrow biopsies from 40 children with newly diagnosed, u

48 n factor (MITF), is highly expressed in bone marrow biopsies from 9 of 10 patients with systemic mast

49 Evaluation of bone marrow biopsies from myeloma patients revealed a strong

50 Moreover, analysis of bone marrow biopsies from myeloma patients reveals a positive

51 In bone marrow biopsies from patients with DBA or del(5q) myelod

52 taneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokin

53 tochemical paraffin section staining of bone marrow biopsies in the staging of B-cell malignant lymph

54 Although bone marrow biopsies in these patients showed increased numbe

55 imal test indicating the necessity of a bone marrow biopsy in ISM-suspected patients.

56 only used test to estimate the need for bone marrow biopsy in patients suspected to have indolent sys

57 r DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogeneity

58 ected by immunohistochemistry in normal bone marrow biopsies, indicating an in vivo function.

59 response to therapy; also, the role of bone marrow biopsy is being revisited.

60 A bone marrow biopsy is no longer indicated for the routine sta

61 Bone marrow biopsies largely replaced by PCa were analyzed us

62 Bone marrow biopsy may reveal hemophagocytosis and marrow his

63 se activity in the plasma isolated from bone marrow biopsies of 100 patients reveals 86 positive for

64 dominant clonotypes in blood and in historic marrow biopsies of 35 AA, 37 MDS, and 21 paroxysmal noct

65 quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilitate i

66 cutoff correctly classifies diagnostic bone marrow biopsies of MPN,U patients specified upon follow-

67 In this investigation, bone marrow biopsies of the anterior iliac crest were examine

68 Responses were assessed by bone marrow biopsy on day 15 of the first course and by clini

69 features with the exception that their bone marrow biopsy pathology revealed abundant neutrophils co

70 Bone marrow biopsy performed in two of these five patients sh

71 Cr corresponded with the high degree of bone marrow biopsies positive for atypical mast cells, the pr

72 aged using clinical assessment, CT, and bone marrow biopsy (RATHL stage).

73 Bone marrow biopsy revealed hypercellular marrow.

74 Bone marrow biopsy revealed no evidence of infectious or neop

75 MAC loads in bilateral bone marrow biopsy samples from 7 subjects were highly correl

76 Early in treatment, marrow biopsies showed increased megakaryocyte number an

77 Serial bone marrow biopsies showed normalization of trilineage hemat

78 Comparison with bone marrow biopsies showed that FDG-PET was not reliable for

79 Bone marrow biopsy showed 60% infiltration with lambda light

80 Immunohistochemistry of bone marrow biopsy showed an increased number of plasma cells

81 In 3 patients the marrow biopsy specimen was positive but the PET scan nor

82 After histologic analysis of the bone marrow biopsy specimen, diagnosis of Waldenstrom macrogl

83 In this study, bone marrow biopsy specimens from 36 patients with T-cell GLL

84 TMA was constructed using pretreatment bone marrow biopsy specimens from 64 adult patients with ALL.

85 e were detected on peripheral smear and bone marrow biopsy specimens, and PCR amplified Ehrlichia ewi

86 gs, and immunohistochemical staining of bone marrow biopsy specimens.

87 Analysis of bone marrow-biopsy specimens obtained from two patients at th

88 Immunohistochemical analysis of bone marrow-biopsy specimens showed that only myeloma cells c

89 These data suggest that bone marrow biopsy using antigen-targeted magnetic nanopartic

90 Bone marrow biopsy was done on day -7 to estimate radiation d

91 nondiagnostic, and lumbar puncture and bone marrow biopsies were negative.

92 With informed consent, marrow biopsies were obtained to collect prostate tumor.

93 One hundred eighty-four bone marrow biopsies were obtained, and 48 had prostate tumor

94 Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer pati

95 GFR-expressing tumor declined on serial bone marrow biopsies with combination therapy alone.